| Systematic (IUPAC) name | |
|---|---|
| 3-(cyclopropylmethyl)- 6,11-dimethyl- 1,2,3,4,5,6-hexahydro- 2,6-methano- 3-benzazocin- 8-ol or 2-cyclopropylmethyl- 2'-hydroxy- 5,9-dimethyl- 6,7-benzomorphan |
|
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Oral |
| Identifiers | |
| CAS number | 7346-09-0 |
| ATC code | None |
| PubChem | CID 19143 |
| IUPHAR ligand | 1604 |
| ChemSpider | 18063 |
| UNII | J5W1B1159C |
| KEGG | D03618 |
| ChEMBL | CHEMBL279449 |
| Chemical data | |
| Formula | C18H25NO |
| Mol. mass | 271.40 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Cyclazocine is a mixed opioid agonist/antagonist related to dezocine, pentazocine and phenazocine. This family of opioid drugs is called the benzomorphans or benzazocines.[1]
Contents |
Research into the use of cyclazocine for the treatment of bipolar patients with depression was undertaken by Fink and colleagues (1970). It showed that 8 out of 10 patients experienced moderate improvement.
Research during the 1960s and 1970s into the possible use of cyclazocine for management of pain, and later for assisting treatment of narcotic addiction was severely hampered by the drug's psychotomimetic, dysphoric, and hallucinatory effects.[2]
Dosages of 1–3 mg were administered in the tests.
|
||||||||||||||||||||||||||||||||||